Literature DB >> 10447764

Lipopolysaccharide enhances FcgammaR-dependent functions in vivo through CD11b/CD18 up-regulation.

C Rubel1, P Miliani De Marval, M Vermeulen, M A Isturiz, M S Palermo.   

Abstract

Fc receptors for immunoglobulin G (IgG) (FcgammaR) mediate several defence mechanisms in the course of inflammatory and infectious diseases. In Gram-negative infections, cellular wall lipopolysaccharides (LPS) modulate different immune responses. We have recently demonstrated that murine LPS in vivo treatment significantly increases FcgammaR-dependent clearance of immune complexes (IC). In addition, we and others have reported the induction of adhesion molecules on macrophages and neutrophils by LPS in vivo and by tumour necrosis factor-alpha (TNF-alpha) in vitro. The aim of this paper was to investigate CD11b/CD18 participation in LPS enhancing effects on Fcgamma-dependent functionality of tissue macrophages. Our results have demonstrated that LPS can enhance antibody-dependent cellular cytotoxicity (ADCC) and IC-triggered cytotoxicity (IC-Ctx), two reactions which involve the Fcgamma-receptor but different lytic mechanisms. In vitro incubation of splenocytes from LPS-treated mice with anti-CD11b/CD18 abrogated ADCC and IC-Ctx enhancement, without affecting FcgammaR expression. Similar results were obtained with physiological concentrations of fibrinogen. In this way cytotoxic values of LPS-splenocytes decreased to the basal levels of control mice. Time and temperature requirements for such inhibition strongly suggested that anti-CD11b/CD18 could modulate intracellular signals leading to downregulation of FcgammaR functionality. Data presented herein support the hypothesis that functional and/or physical associations between integrins and FcgammaR could be critical for the modulation of effector functions during an inflammatory response.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10447764      PMCID: PMC2326862          DOI: 10.1046/j.1365-2567.1999.00788.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  42 in total

1.  Different signaling pathways for CD18-mediated adhesion and Fc-mediated phagocytosis. Response of neutrophils to LPS.

Authors:  P A Detmers; D Zhou; D E Powell
Journal:  J Immunol       Date:  1994-09-01       Impact factor: 5.422

2.  A novel leukointegrin, alpha d beta 2, binds preferentially to ICAM-3.

Authors:  M Van der Vieren; H Le Trong; C L Wood; P F Moore; T St John; D E Staunton; W M Gallatin
Journal:  Immunity       Date:  1995-12       Impact factor: 31.745

Review 3.  Integrins and signal transduction pathways: the road taken.

Authors:  E A Clark; J S Brugge
Journal:  Science       Date:  1995-04-14       Impact factor: 47.728

4.  L-selectin (CD62L) cross-linking signals neutrophil adhesive functions via the Mac-1 (CD11b/CD18) beta 2-integrin.

Authors:  S I Simon; A R Burns; A D Taylor; P K Gopalan; E B Lynam; L A Sklar; C W Smith
Journal:  J Immunol       Date:  1995-08-01       Impact factor: 5.422

5.  Temporal down-regulation of Fc gamma RIII expression and Fc gamma receptor-mediated phagocytosis in human monocyte-derived macrophages induced by TNF-alpha and IL-1 beta.

Authors:  G Liao; S R Simon
Journal:  J Leukoc Biol       Date:  1994-06       Impact factor: 4.962

Review 6.  Role of Fc gamma receptors in cancer and infectious disease.

Authors:  P K Wallace; A L Howell; M W Fanger
Journal:  J Leukoc Biol       Date:  1994-06       Impact factor: 4.962

7.  Expression of homing and adhesion molecules in infiltrated islets of Langerhans and salivary glands of nonobese diabetic mice.

Authors:  C Faveeuw; M C Gagnerault; F Lepault
Journal:  J Immunol       Date:  1994-06-15       Impact factor: 5.422

8.  Granulocyte activation via a binding site near the C-terminal region of complement receptor type 3 alpha-chain (CD11b) potentially involved in intramembrane complex formation with glycosylphosphatidylinositol-anchored Fc gamma RIIIB (CD16) molecules.

Authors:  J Stöckl; O Majdic; W F Pickl; A Rosenkranz; E Prager; E Gschwantler; W Knapp
Journal:  J Immunol       Date:  1995-05-15       Impact factor: 5.422

9.  Activation of human neutrophils through L-selectin and Mac-1 molecules.

Authors:  E Crockett-Torabi; B Sulenbarger; C W Smith; J C Fantone
Journal:  J Immunol       Date:  1995-03-01       Impact factor: 5.422

10.  Regulation of intracellular polymorphonuclear leukocyte Fc receptors by lipopolysaccharide.

Authors:  H H Simms; R D'Amico
Journal:  Cell Immunol       Date:  1994-09       Impact factor: 4.868

View more
  4 in total

1.  Binding of recombinant T cell receptor ligands (RTL) to antigen presenting cells prevents upregulation of CD11b and inhibits T cell activation and transfer of experimental autoimmune encephalomyelitis.

Authors:  Sushmita Sinha; Lisa Miller; Sandhya Subramanian; Owen J T McCarty; Thomas Proctor; Roberto Meza-Romero; Jianya Huan; Gregory G Burrows; Arthur A Vandenbark; Halina Offner
Journal:  J Neuroimmunol       Date:  2010-05-23       Impact factor: 3.478

2.  Opsonization effects on Mycobacterium avium subsp. paratuberculosis--macrophage interactions.

Authors:  J Hostetter; R Kagan; E Steadham
Journal:  Clin Diagn Lab Immunol       Date:  2005-06

3.  Chronic Porphyromonas gingivalis lipopolysaccharide induces adverse myocardial infarction wound healing through activation of CD8+ T cells.

Authors:  Yusra Zaidi; Alexa Corker; Valeriia Y Vasileva; Kimberly Oviedo; Connor Graham; Kyrie Wilson; John Martino; Miguel Troncoso; Philip Broughton; Daria V Ilatovskaya; Merry L Lindsey; Kristine Y DeLeon-Pennell
Journal:  Am J Physiol Heart Circ Physiol       Date:  2021-10-01       Impact factor: 5.125

4.  CD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytes.

Authors:  Wei Hseun Yeap; Kok Loon Wong; Noriko Shimasaki; Esmeralda Chi Yuan Teo; Jeffrey Kim Siang Quek; Hao Xiang Yong; Colin Phipps Diong; Antonio Bertoletti; Yeh Ching Linn; Siew Cheng Wong
Journal:  Sci Rep       Date:  2016-09-27       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.